Company intelligence / Profile preview

Efung Capital

Shenzhen, Guangdong, Chinaen.efungcapital.com ↗

Ownership: Private
Development stage: Other

Overview

Efung Capital is one of the earliest and most recognized healthcare-focused venture capital firms in China. It has invested in over 80 high-quality domestic and international biopharmaceutical and medical device companies. Its investments span from early clinical to late-stage/commercialization programs across oncology, autoimmune disease, antivirals and more. The firm has received multiple industry awards for its investment performance.

Therapeutic areas: OncologyImmunologyGastroenterologyInfectious Diseases
Modalities: Small moleculeMonoclonal antibodyBispecific monoclonal antibodyProtein therapeuticsBiologicsMedical devicesGene therapyCell therapy
Industry: Investors

Partnerships

Co-investments with major Chinese VCs such as HongShan/SBCVC/Dingxin Capital/Qingsong Capital/etc.

Beyond the preview

Go deeper on Efung Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Efung Capital.

Explore the full profile